{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:51:31Z","timestamp":1793911891010,"version":"4.8.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Aberrant RNA alternative splicing in cancer generates varied novel isoforms and protein variants that facilitate cancer progression. Here, we employed the advanced long-read full-length transcriptome sequencing on gallbladder normal tissues, tumors, and cell lines to establish a comprehensive full-length gallbladder transcriptomic atlas. It is of note that receptor tyrosine kinases were one of the most dynamic components with highly variable transcript, with Erb-B2 receptor tyrosine kinase 2 (ERBB2) as a prime representative. A novel transcript, designated ERBB2 i14e, was identified for encoding a novel functional protein, and its protein expression was elevated in gallbladder cancer and strongly associated with worse prognosis. With the regulation of splicing factors ESRP1\/2, ERBB2 i14e was alternatively spliced from intron 14 and the encoded i14e peptide was proved to facilitate the interaction with ERBB3 and downstream signaling activation of AKT. ERBB2 i14e was inducible and its expression attenuated anti-ERBB2 treatment efficacy in tumor xenografts. Further studies with patient derived xenografts models validated that ERBB2 i14e blockage with antisense oligonucleotide enhanced the tumor sensitivity to trastuzumab and its drug conjugates. Overall, this study provides a gallbladder specific long-read transcriptome profile and discovers a novel mechanism of trastuzumab resistance, thus ultimately devising strategies to improve trastuzumab therapy.<\/jats:p>","DOI":"10.1038\/s41392-025-02150-w","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:01:59Z","timestamp":1739491319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing"],"prefix":"10.1038","volume":"10","author":[{"given":"Ziyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziheng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaonan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-6947","authenticated-orcid":false,"given":"Yanjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-8739","authenticated-orcid":false,"given":"Wu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"2150_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","volume":"8","author":"JC Roa","year":"2022","unstructured":"Roa, J. C. et al. Gallbladder cancer. Nat. Rev. Dis. Prim. 8, 69 (2022).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2150_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle, J. W., Kelley, R. K., Nervi, B., Oh, D. Y. & Zhu, A. X. Biliary tract cancer. Lancet 397, 428\u2013444 (2021).","journal-title":"Lancet"},{"key":"2150_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41392-020-00324-2","volume":"5","author":"X Song","year":"2020","unstructured":"Song, X. et al. Overview of current targeted therapy in gallbladder cancer. Signal Transduct. Target Ther. 5, 230 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2150_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrc3277","volume":"12","author":"JB Casaletto","year":"2012","unstructured":"Casaletto, J. B. & McClatchey, A. I. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat. Rev. Cancer 12, 387\u2013400 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"2150_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du, Z. & Lovly, C. M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer 17, 58 (2018).","journal-title":"Mol. Cancer"},{"key":"2150_CR6","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","volume":"40","author":"P Saraon","year":"2021","unstructured":"Saraon, P. et al. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene 40, 4079\u20134093 (2021).","journal-title":"Oncogene"},{"key":"2150_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"Tomuleasa, C. et al. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct. Target Ther. 9, 201 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2150_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341\u2013354 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"2150_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ceb.2008.12.010","volume":"21","author":"NE Hynes","year":"2009","unstructured":"Hynes, N. E. & MacDonald, G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21, 177\u2013184 (2009).","journal-title":"Curr. Opin. Cell Biol."},{"key":"2150_CR10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3030","volume":"46","author":"M Li","year":"2014","unstructured":"Li, M. et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat. Genet. 46, 872\u2013876 (2014).","journal-title":"Nat. Genet."},{"key":"2150_CR11","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/gutjnl-2018-316039","volume":"68","author":"M Li","year":"2019","unstructured":"Li, M. et al. Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut 68, 1024\u20131033 (2019).","journal-title":"Gut"},{"key":"2150_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.21037\/hbsn.2019.04.11","volume":"8","author":"P Yang","year":"2019","unstructured":"Yang, P. et al. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg. Nutr. 8, 604\u2013614 (2019).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"2150_CR13","first-page":"6971","volume":"61","author":"K Kiguchi","year":"2001","unstructured":"Kiguchi, K. et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 61, 6971\u20136976 (2001).","journal-title":"Cancer Res."},{"key":"2150_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","volume":"8","author":"M Javle","year":"2015","unstructured":"Javle, M. et al. HER2\/neu-directed therapy for biliary tract cancer. J. Hematol. Oncol. 8, 58 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"2150_CR15","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","volume":"36","author":"JD Hainsworth","year":"2018","unstructured":"Hainsworth, J. D. et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an Open-Label, Phase IIa multiple basket study. J. Clin. Oncol. 36, 536\u2013542 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2150_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature25475","volume":"554","author":"DM Hyman","year":"2018","unstructured":"Hyman, D. M. et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554, 189\u2013194 (2018).","journal-title":"Nature"},{"key":"2150_CR17","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1200\/JCO.2018.36.15_suppl.2500","volume":"36","author":"Funda Meric-Bernstam","year":"2018","unstructured":"Meric-Bernstam, Funda et al. Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. J. Clin. Oncol. 36, 2500 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2150_CR18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/annonc\/mdl475","volume":"18","author":"G Valabrega","year":"2007","unstructured":"Valabrega, G., Montemurro, F. & Aglietta, M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 18, 977\u2013984 (2007).","journal-title":"Ann. Oncol."},{"key":"2150_CR19","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.3390\/cancers13143540","volume":"13","author":"H Maadi","year":"2021","unstructured":"Maadi, H., Soheilifar, M. H., Choi, W.-S., Moshtaghian, A. & Wang, Z. Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. Cancers 13, 3540 (2021).","journal-title":"Cancers"},{"key":"2150_CR20","first-page":"19","volume":"1","author":"R Bartsch","year":"2007","unstructured":"Bartsch, R., Wenzel, C. & Steger, G. G. Trastuzumab in the management of early and advanced stage breast cancer. Biologics 1, 19\u201331 (2007).","journal-title":"Biologics"},{"key":"2150_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","volume":"19","author":"A Friedlaender","year":"2022","unstructured":"Friedlaender, A. et al. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat. Rev. Clin. Oncol. 19, 51\u201369 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2150_CR22","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1038\/sj.emboj.7601191","volume":"25","author":"J Anido","year":"2006","unstructured":"Anido, J. et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 25, 3234\u20133244 (2006).","journal-title":"EMBO J."},{"key":"2150_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4143-x","volume":"18","author":"H Maadi","year":"2018","unstructured":"Maadi, H., Nami, B., Tong, J., Li, G. & Wang, Z. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. BMC Cancer 18, 238 (2018).","journal-title":"BMC Cancer"},{"key":"2150_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44533-z","volume":"15","author":"GD Lewis","year":"2024","unstructured":"Lewis, G. D. et al. The HER2-directed antibody-drug conjugate DHES0815A in advanced and\/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nat. Commun. 15, 466 (2024).","journal-title":"Nat. Commun."},{"key":"2150_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01459-y","volume":"23","author":"E Ferraro","year":"2021","unstructured":"Ferraro, E., Drago, J. Z. & Modi, S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res. 23, 84 (2021).","journal-title":"Breast Cancer Res."},{"key":"2150_CR26","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat. Med. 30, 2208\u20132215 (2024).","journal-title":"Nat. Med."},{"key":"2150_CR27","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/2159-8290.CD-23-0282","volume":"13","author":"M Zhang","year":"2023","unstructured":"Zhang, M. et al. An inflammatory checkpoint generated by IL1RN splicing offers therapeutic opportunity for KRAS-mutant intrahepatic cholangiocarcinoma. Cancer Discov. 13, 2248\u20132269 (2023).","journal-title":"Cancer Discov."},{"key":"2150_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01226-y","volume":"15","author":"Q Sun","year":"2023","unstructured":"Sun, Q. et al. Long-read sequencing reveals the landscape of aberrant alternative splicing and novel therapeutic target in colorectal cancer. Genome Med. 15, 76 (2023).","journal-title":"Genome Med."},{"key":"2150_CR29","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41596-023-00944-2","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. rMATS-turbo: an efficient and flexible computational tool for alternative splicing analysis of large-scale RNA-seq data. Nat. Protoc. 19, 1083\u20131104 (2024).","journal-title":"Nat. Protoc."},{"key":"2150_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tibtech.2018.07.013","volume":"37","author":"A Ameur","year":"2019","unstructured":"Ameur, A., Kloosterman, W. P. & Hestand, M. S. Single-molecule sequencing: towards clinical applications. Trends Biotechnol. 37, 72\u201385 (2019).","journal-title":"Trends Biotechnol."},{"key":"2150_CR31","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.tig.2018.05.008","volume":"34","author":"EL van Dijk","year":"2018","unstructured":"van Dijk, E. L., Jaszczyszyn, Y., Naquin, D. & Thermes, C. The third revolution in sequencing technology. Trends Genet. 34, 666\u2013681 (2018).","journal-title":"Trends Genet."},{"key":"2150_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/cancers16071275","volume":"16","author":"L Ermini","year":"2024","unstructured":"Ermini, L. & Driguez, P. The application of long-read sequencing to cancer. Cancers 16, 1275 (2024).","journal-title":"Cancers"},{"key":"2150_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.994087","volume":"12","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Establishment and characterization of an immortalized epithelial cell line from human gallbladder. Front. Oncol. 12, 994087 (2022).","journal-title":"Front. Oncol."},{"key":"2150_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02261-x","volume":"22","author":"KK Huang","year":"2021","unstructured":"Huang, K. K. et al. Long-read transcriptome sequencing reveals abundant promoter diversity in distinct molecular subtypes of gastric cancer. Genome Biol. 22, 44 (2021).","journal-title":"Genome Biol."},{"key":"2150_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2006-7-2-206","volume":"7","author":"E Kruse","year":"2006","unstructured":"Kruse, E., Uehlein, N. & Kaldenhoff, R. The aquaporins. Genome Biol. 7, 206 (2006).","journal-title":"Genome Biol."},{"key":"2150_CR36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jhep.2020.10.010","volume":"74","author":"DC Trampert","year":"2021","unstructured":"Trampert, D. C., van de Graaf, S. F. J., Jongejan, A., Oude Elferink, R. P. J. & Beuers, U. Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia. J. Hepatol. 74, 428\u2013441 (2021).","journal-title":"J. Hepatol."},{"key":"2150_CR37","first-page":"G628","volume":"269","author":"SA Wank","year":"1995","unstructured":"Wank, S. A. Cholecystokinin receptors. Am. J. Physiol. 269, G628\u2013G646 (1995).","journal-title":"Am. J. Physiol."},{"key":"2150_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ydbio.2007.05.028","volume":"308","author":"MP Hunter","year":"2007","unstructured":"Hunter, M. P. et al. The homeobox gene Hhex is essential for proper hepatoblast differentiation and bile duct morphogenesis. Dev. Biol. 308, 355\u2013367 (2007).","journal-title":"Dev. Biol."},{"key":"2150_CR39","doi-asserted-by":"publisher","first-page":"e1002754","DOI":"10.1371\/journal.pgen.1002754","volume":"8","author":"M Delous","year":"2012","unstructured":"Delous, M. et al. Sox9b is a key regulator of pancreaticobiliary ductal system development. PLoS Genet. 8, e1002754 (2012).","journal-title":"PLoS Genet."},{"key":"2150_CR40","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","volume":"18","author":"Z Sondka","year":"2018","unstructured":"Sondka, Z. et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696\u2013705 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2150_CR41","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jhep.2021.06.023","volume":"75","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer. J. Hepatol. 75, 1128\u20131141 (2021).","journal-title":"J. Hepatol."},{"key":"2150_CR42","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1073\/pnas.1537685100","volume":"100","author":"T Holbro","year":"2003","unstructured":"Holbro, T. et al. The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl Acad. Sci. USA 100, 8933\u20138938 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2150_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.critrevonc.2019.05.001","volume":"139","author":"C Vernieri","year":"2019","unstructured":"Vernieri, C. et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Crit. Rev. Oncol. Hematol. 139, 53\u201366 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2150_CR44","doi-asserted-by":"crossref","unstructured":"Duan, N. et al. Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary Trastuzumab Adaptation of HER2-Positive Breast Cancer. Adv. Sci. 11, 2309424 (2024).","DOI":"10.1002\/advs.202309424"},{"key":"2150_CR45","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015872","volume":"98","author":"J Wang","year":"2019","unstructured":"Wang, J., Xu, R., Yuan, H., Zhang, Y. & Cheng, S. Single-cell RNA sequencing reveals novel gene expression signatures of trastuzumab treatment in HER2+ breast cancer: a pilot study. Medicine 98, e15872 (2019).","journal-title":"Medicine"},{"key":"2150_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07540-7","volume":"20","author":"K Ebert","year":"2020","unstructured":"Ebert, K. et al. Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines. BMC Cancer 20, 1039 (2020).","journal-title":"BMC Cancer"},{"key":"2150_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.canlet.2020.11.043","volume":"501","author":"J-X Du","year":"2021","unstructured":"Du, J.-X. et al. Splicing factors: Insights into their regulatory network in alternative splicing in cancer. Cancer Lett. 501, 83\u2013104 (2021).","journal-title":"Cancer Lett."},{"key":"2150_CR48","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.molcel.2023.06.003","volume":"83","author":"I Beusch","year":"2023","unstructured":"Beusch, I. et al. Targeted high-throughput mutagenesis of the human spliceosome reveals its in vivo operating principles. Mol. Cell 83, 2578\u20132594.e2579 (2023).","journal-title":"Mol. Cell"},{"key":"2150_CR49","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1042\/BST20221124","volume":"51","author":"JM Derham","year":"2023","unstructured":"Derham, J. M. & Kalsotra, A. The discovery, function, and regulation of epithelial splicing regulatory proteins (ESRP) 1 and 2. Biochem. Soc. Trans. 51, 1097\u20131109 (2023).","journal-title":"Biochem. Soc. Trans."},{"key":"2150_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105205","volume":"25","author":"NJ Peart","year":"2022","unstructured":"Peart, N. J. et al. The global Protein-RNA interaction map of ESRP1 defines a post-transcriptional program that is essential for epithelial cell function. iScience 25, 105205 (2022).","journal-title":"iScience"},{"key":"2150_CR51","doi-asserted-by":"publisher","first-page":"232","DOI":"10.31662\/jmaj.2021-0019","volume":"4","author":"M Matsuo","year":"2021","unstructured":"Matsuo, M. Antisense oligonucleotide-mediated exon-skipping therapies: precision medicine spreading from duchenne muscular dystrophy. JMA J. 4, 232\u2013240 (2021).","journal-title":"JMA J."},{"key":"2150_CR52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.yexcr.2014.01.026","volume":"325","author":"M Veltrop","year":"2014","unstructured":"Veltrop, M. & Aartsma-Rus, A. Antisense-mediated exon skipping: taking advantage of a trick from Mother Nature to treat rare genetic diseases. Exp. Cell Res. 325, 50\u201355 (2014).","journal-title":"Exp. Cell Res."},{"key":"2150_CR53","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41586-022-05325-5","volume":"611","author":"ED Jarvis","year":"2022","unstructured":"Jarvis, E. D. et al. Semi-automated assembly of high-quality diploid human reference genomes. Nature 611, 519\u2013531 (2022).","journal-title":"Nature"},{"key":"2150_CR54","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41586-023-05896-x","volume":"617","author":"WW Liao","year":"2023","unstructured":"Liao, W. W. et al. A draft human pangenome reference. Nature 617, 312\u2013324 (2023).","journal-title":"Nature"},{"key":"2150_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/cco.2019.08.13","volume":"8","author":"MA Schmidt","year":"2019","unstructured":"Schmidt, M. A., Marcano-Bonilla, L. & Roberts, L. R. Gallbladder cancer: epidemiology and genetic risk associations. Chin. Clin. Oncol. 8, 31 (2019).","journal-title":"Chin. Clin. Oncol."},{"key":"2150_CR56","doi-asserted-by":"publisher","first-page":"2050313X2211374","DOI":"10.1177\/2050313X221137447","volume":"10","author":"V Lavingia","year":"2022","unstructured":"Lavingia, V., Thummar, V. & Mehta, P. Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2-overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: a case study. SAGE Open Med. Case Rep. 10, 2050313X221137447 (2022).","journal-title":"SAGE Open Med. Case Rep."},{"key":"2150_CR57","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/onco.13800","volume":"26","author":"M May","year":"2021","unstructured":"May, M. et al. Prolonged response to HER2-Directed therapy in three patients with HER2-Amplified metastatic carcinoma of the biliary system: case study and review of the literature. Oncologist 26, 640\u2013646 (2021).","journal-title":"Oncologist"},{"key":"2150_CR58","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41392-019-0069-2","volume":"4","author":"JN Wang","year":"2019","unstructured":"Wang, J. N. & Xu, B. H. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct. Target Ther. 4, 34 (2019).","journal-title":"Signal Transduct. Target Ther."},{"key":"2150_CR59","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41586-021-04084-z","volume":"600","author":"D Diwanji","year":"2021","unstructured":"Diwanji, D. et al. Structures of the HER2-HER3-NRG1beta complex reveal a dynamic dimer interface. Nature 600, 339\u2013343 (2021).","journal-title":"Nature"},{"key":"2150_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.678","volume":"12","author":"B Yuan","year":"2022","unstructured":"Yuan, B. et al. Patient-derived organoids for personalized gallbladder cancer modelling and drug screening. Clin. Transl. Med. 12, e678 (2022).","journal-title":"Clin. Transl. Med."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02150-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:02:04Z","timestamp":1739491324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02150-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2150"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02150-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"8 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Normal gallbladders from organ donors and tissues from patients diagnosed with GBC were collected with signed consent. The request for samples and corresponding clinical data was reviewed and approved by Shanghai Jiao Tong University School of Medicine, Renji Hospital Ethics Committee (KY2020-208; KY2022-182-B; KY2023-065-C). The animal study was reviewed and approved by the Institutional Animal Care and Use Committee of Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine. All animal experiments complied with ARRIVE guidelines (RJ-2024-029-A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"54"}}